# Julio Rosenstock

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/julio-rosenstock/

## Facts

| Field | Value |
| --- | --- |
| Citations | 68,054 |
| Field | Diabetes Treatment and Management |
| h-index | 120 |
| i10-index | 327 |
| Last Known Institution | Dallas Diabetes Research Center |
| OpenAlex ID | https://openalex.org/A5045489578 |
| ORCID iD | 0000-0001-8324-3275 |
| Works | 691 |

## Researcher papers

Showing 12 of 28.

- [Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [Once-Weekly Semaglutide in Adults with Overweight or Obesity](https://scholariq.org/papers/once-weekly-semaglutide-in-adults-with-overweight-or-obesity/)
- [Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-a-double-blind/)
- [Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes](https://scholariq.org/papers/tirzepatide-versus-semaglutide-once-weekly-in-patients-with-type-2-diabetes/)
- [Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials](https://scholariq.org/papers/cardiovascular-mortality-and-kidney-outcomes-with-glp-1-receptor-agonists-in-2/)
- [Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)](https://scholariq.org/papers/liraglutide-once-a-day-versus-exenatide-twice-a-day-for-type-2-diabetes-a-26/)
- [The Treat-to-Target Trial](https://scholariq.org/papers/the-treat-to-target-trial/)
- [Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial](https://scholariq.org/papers/semaglutide-2-4-mg-once-a-week-in-adults-with-overweight-or-obesity-and-type-2/)
- [Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients](https://scholariq.org/papers/effect-of-rimonabant-a-cannabinoid-1-receptor-blocker-on-weight-and/)
- [Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea](https://scholariq.org/papers/effects-of-exenatide-exendin-4-on-glycemic-control-over-30-weeks-in-patients/)
- [Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk](https://scholariq.org/papers/effect-of-linagliptin-vs-placebo-on-major-cardiovascular-events-in-adults-with/)
- [Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension](https://scholariq.org/papers/weight-regain-and-cardiometabolic-effects-after-withdrawal-of-semaglutide-the/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)

## Researcher university

- [Dallas Diabetes Research Center](https://scholariq.org/institutions/dallas-diabetes-research-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.